Foundation Medicine Launches ICE 2, Its New Version of Interactive Cancer Explorer, Featuring PatientMatch

Foundation Medicine Launches ICE 2, Its New Version of Interactive Cancer Explorer, Featuring PatientMatch

ICE 2 Enables Physicians To More Effectively Leverage Comprehensive Genomic Profiling In Their Practices

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc. (FMI) announced the recent launch of ICE 2™, the newest version of its Interactive Cancer Explorer® (ICE) physician portal. ICE 2 is designed to enable physicians to increase the efficiency of patient care utilizing Foundation Medicine tests and to enhance the utility of comprehensive genomic profiling. Among other updates, ICE 2 features PatientMatch™ – a feature that leverages Foundation Medicine's growing knowledgebase of more than 30,000 genomic profiles to help increase the actionability of FoundationOne® and FoundationOne Heme results. Using PatientMatch, physicians within the Foundation Medicine network are able to connect with other physicians treating patients with similar genomic/tumor profiles to share treatment and outcomes information in a compliant manner.

"By releasing ICE 2, Foundation Medicine is again demonstrating our commitment to innovation and to making molecular information more broadly available to the oncology community," said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. "This new platform allows physicians, in a HIPAA compliant fashion, to access results from our FoundationOne and FoundationOne Heme comprehensive genomic profiling tests, obtain critical evidence-based information about potential treatment options and clinical trials, and connect with other physicians who have treated similar patients, exchanging genomic information, treatment and outcomes data. The ability to exchange information real time and learn from one another must be an essential component of this transformation in cancer care, which is rapidly moving toward a precision-based approach. As we continue to see increased adoption of Foundation Medicine's comprehensive genomic profiling within the clinical setting, we are pleased to make ICE 2 available, creating a stronger, more engaged network of physicians and ultimately, enabling more informed treatment options for patients."

First launched in 2012, Foundation Medicine's online portal gives physicians access to test reports from FoundationOne and FoundationOne Heme on their tablet, computer or mobile device. ICE 2 offers several new features that increase the efficiency of patient care, including sample tracking, notifications and enhanced search, which allows physicians to find patients by gene, alteration or tumor type. In addition, ICE 2 features a brand new service called PatientMatch that identifies and connects physicians across Foundation Medicine's network who have seen patients with similar genomic profiles and tumor types, allowing them to share clinical experiences and outcomes data to help inform treatment decisions.

To learn more about ICE 2, please visit http://foundationone.com/learn.php#4.

About FoundationOne^®

FoundationOne, the company's first clinical product, is a fully informative genomic profile for solid tumors used by oncologists to identify the molecular alterations in a patient's tumor and match those alterations with relevant targeted therapies and clinical trials. Using next-generation sequencing in routine cancer specimens, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. FoundationOne fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne is a laboratory-developed test performed at Foundation Medicine's CLIA-certified lab. The test is accredited by CAP, is approved by the New York State Department of Health and has received a CE Mark. Please visit www.FoundationOne.com for more information.

About FoundationOne^® Heme

FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. It is Foundation Medicine's second commercially available targeted sequencing assay and was developed in collaboration with Memorial Sloan Kettering Cancer Center. Using next-generation sequencing in routine cancer specimens, FoundationOne Heme interrogates all genes somatically altered in these cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. The test employs RNA sequencing in addition to DNA sequencing to simultaneously detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions (a type of alteration that is a common driver of hematologic malignancies, sarcomas and pediatric cancers). FoundationOne Heme fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne Heme is a laboratory-developed test performed at Foundation Medicine's CLIA-certified lab. Please visit www.FoundationOne.com for more information.

About Foundation Medicine

Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine^® and FoundationOne^® are registered trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements for Foundation Medicine

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the launch of a new version of Interactive Cancer Explorer, the ability of ICE 2 assist physicians in providing care to cancer patients using Foundation Medicine's comprehensive genomic profiling, and the potential impact of current and future enhancements to patient treatment. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that ICE 2 does not perform as expected; that subsequent enhancements to Interactive Cancer Explorer are not developed; that future versions of Interactive Cancer Explorer do not impact the treatment of cancer; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.